Xuantai Pharmaceutical announced that the company's product, posaconazole enteric tablets, recently passed the EU's decentralized approval process and obtained marketing permits in the Netherlands, Germany, Spain, France and Italy. This drug is mainly used to treat aggressive aspergillus or candida infections. It is the first generic approved by the US FDA and the Chinese NMPA. It has previously been approved in Australia, Singapore, Saudi Arabia, Israel, Canada, and Vietnam. This approval indicates that the company is qualified to sell this product in the above 5 countries, which is conducive to expanding the sales scale in the European market, but there is uncertainty about the impact on performance in the short term.

Xuantai Pharmaceutical announced that the company's product, posaconazole enteric tablets, recently passed the EU's decentralized approval process and obtained marketing permits in the Netherlands, Germany, Spain, France and Italy. This drug is mainly used to treat aggressive aspergillus or candida infections. It is the first generic approved by the US FDA and the Chinese NMPA. It has previously been approved in Australia, Singapore, Saudi Arabia, Israel, Canada, and Vietnam. This approval indicates that the company is qualified to sell this product in the above 5 countries, which is conducive to expanding the sales scale in the European market, but there is uncertainty about the impact on performance in the short term.